期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 38, 期 5, 页码 438-447出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2017.02.002
关键词
-
资金
- NIH [GM 43154]
- National Cancer Institute [ZIA BC 011691]
- Cancer Research UK
- Cancer Research UK [12936] Funding Source: researchfish
The discovery in the 1980s that protein kinase C (PKC) is a receptor for the tumor-promoting phorbol esters fueled the dogma that PKC is an oncoprotein. Yet 30+ years of clinical trials for cancer using PKC inhibitors not only failed, but in some instances worsened patient outcome. The recent analysis of cancer-associated mutations, from diverse cancers and throughout the PKC family, revealed that PKC isozymes are generally inactivated in cancer, supporting a tumor suppressive function. In keeping with a bona fide tumor suppressive role, germline causal loss-of-function (LOF) mutations in one isozyme have recently been identified in lymphoproliferative disorders. Thus, strategies in cancer treatment should focus on restoring rather than inhibiting PKC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据